LifeHealthcare Group Limited (ASX:LHC) announces its results for the half year ending 31 December 2017.
Financial Results
LifeHealthcare delivered solid revenue growth and strong underlying earnings and NPATA growth for the period. Revenue growth of 9.3% (3.4% organic growth) on the prior comparable period to $67.4 million was achieved with underlying EBITDA growth of 9.9% to $9.8 million and underlying NPATA growth of 10.2% to $4.0 million.
There was an uplift in the gross margin percentage of 2.5% as a result of foreign exchange with the AUD to USD hedging rate improving and a change in product mix due to higher growth in implants than capital products relative to the prior comparable period.
For further information please download PDF attached:
Download this document
